Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA)

As reported by gurufocus.com

On October 01, 2026, Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced a strategic global agreement with Samsung Bioepis Co., Ltd. to develop and commer...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on gurufocus.com ↗

Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.

INDIAN Nifty IT crashes 11% in September: TCS, Infosys, Wipro among top losers — Can Q2 earnings spark a rebound? mint - markets
INDIAN Accenture shares jump 20% in pre-market as Q4 earnings, 2027 outlook beat estimates mint - markets
INDIAN Ace investor Shankar Sharma decodes market performance, highlights where money-making opportunities lie mint - markets
INDIAN Global bond rout hoists benchmark Indian yield to mid-2024 high before RBI policy Markets-Economic Times
INDIAN Rupee slumps 37 paise to close at 96.31 against U.S. dollar Stock Market Today: Sensex, Nifty, BSE, NSE Latest Updates | The Hindu
CRYPTO Morning Minute: Crypto Gives Up on Congress and Goes After Senators Decrypt
CRYPTO Citi Lifts 12-Month Bitcoin Target to $113K, Ethereum to $3K Decrypt
GLOBAL Stocks making the biggest moves premarket: Alphabet, Accenture, Rocket Lab, Micron and more Finance

Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA)

More from Market Samachar